STA
Biogen announces phase 2 data for cutaneous lupus erythematosus
The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved
The real-world findings support the long-term benefits of continuous treatment
Biogen to acquire RayThera in $1bn deal
The acquisition will expand the company’s immunology pipeline
Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA
In the study, there were improvements in motor function as well as a slowing of neurodegeneration
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
Biogen agrees $850m felzartamab rights deal with TJ Biopharma
The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases
MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment
SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK
Biogen to acquire Apellis in $5.6bn deal
The deal will enhance Biogen’s growth portfolio in immunology and rare disease
Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term
The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark